γ-Secretase component presenilin is important for microglia β-amyloid clearance

Annals of Neurology

Volumn 69, Issue 1, 2011, Pages 170-180

  Farfara, Dorit ^a   Trudler, Dorit ^a   Segev Amzaleg, Niva ^a   Galron, Ronit ^a   Stein, Reuven ^a   Frenkel, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; PRESENILIN 1; PRESENILIN 2; SHORT HAIRPIN RNA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CELL ACTIVITY; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; IN VIVO STUDY; MALE; MICROGLIA; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELLS, CULTURED; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; PHAGOCYTOSIS; PLAQUE, AMYLOID; PRESENILINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 79551481336     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22191     Document Type: Article

References (48)

1. Hardy J, Selkoe DJ,. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
2. Lee VM, Trojanowski JQ,. Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J Alzheimers Dis 2006; 9: 257-262.
3. Aliev G, Seyidova D, Lamb BT, et al. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res 2003; 25: 665-674.
4. Sorbi S, Forleo P, Tedde A, et al. Genetic risk factors in familial Alzheimer's disease. Mech Ageing Dev 2001; 122: 1951-1960.
5. Goldman JS, Reed B, Gearhart R, et al. Very early-onset familial Alzheimer's disease: a novel presenilin 1 mutation. Int J Geriatr Psychiatry 2002; 17: 649-651.
6. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-977.
7. Wolfe MS,. Gamma-secretase: structure, function, and modulation for Alzheimer's disease. Curr Top Med Chem 2008; 8: 2-8.
8. Haass C, Selkoe DJ,. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 2007; 8: 101-112.
9. Imbimbo BP,. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008; 8: 54-61.
10. Farfara D, Lifshitz V, Frenkel D,. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 2008; 12: 762-780.
11. Streit WJ,. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 2004; 77: 1-8.
12. El Khoury J, Toft M, Hickman SE, et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007; 13: 432-438.
13. Herreman A, Hartmann D, Annaert W, et al. Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 1999; 96: 11872-11877.
14. Micchelli CA, Esler WP, Kimberly WT, et al. Gamma-secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila. FASEB J 2003; 17: 79-81.
15. McLendon C, Xin T, Ziani-Cherif C, et al. Cell-free assays for gamma-secretase activity. FASEB J. 2000; 14: 2383-2386.
16. Mayo L, Stein R,. Characterization of LPS and interferon-gamma triggered activation-induced cell death in N9 and primary microglial cells: induction of the mitochondrial gateway by nitric oxide. Cell Death Differ 2007; 14: 183-186.
17. Saura J, Tusell JM, Serratosa J,. High-yield isolation of murine microglia by mild trypsinization. Glia 2003; 44: 183-189.
18. Hickman SE, Allison EK, El Khoury J,. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008; 28: 8354-8360.
19. Frenkel D, Puckett L, Petrovic S, et al. A nasal proteosome adjuvant activates microglia and prevents amyloid deposition. Ann Neurol 2008; 63: 591-601.
20. Kimberly WT, Xia W, Rahmati T, et al. The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J Biol Chem 2000; 275: 3173-3178.
21. Chan A, Hummel V, Weilbach FX, et al. Phagocytosis of apoptotic inflammatory cells downregulates microglial chemoattractive function and migration of encephalitogenic T cells. J Neurosci Res 2006; 84: 1217-1224.
22. Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006; 26: 10129-10140.
23. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003; 9: 453-457.
24. Li H, Black NP, Chokshi A, et al. High-throughput screening for fatty acid uptake inhibitors in humanized yeast identifies atypical antipsychotic drugs that cause dyslipidemias. J Lipid Res 2008; 49: 230-244.
25. Lee SC, Zhao ML, Hirano A, Dickson DW,. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus: association with Hirano bodies, neurofibrillary tangles, and senile plaques. J Neuropathol Exp Neurol 1999; 58: 1163-1169.
26. El Khoury J, Hickman SE, Thomas CA, et al. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 1996; 382: 716-719.
27. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003; 100: 4162-4167.
28. Yan P, Hu X, Song H, et al. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 2006; 281: 24566-24574.
29. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730-32738.
30. Qiu WQ, Ye Z, Kholodenko D, et al. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem 1997; 272: 6641-6646.
31. Simard AR, Soulet D, Gowing G, et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006; 49: 489-502.
32. Wan L, Pooyan S, Hu P, et al. Peritoneal macrophage uptake, pharmacokinetics and biodistribution of macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarriers for improving HIV drug delivery. Pharm Res 2007; 24: 2110-2119.
33. Flanary BE, Sammons NW, Nguyen C, et al. Evidence that aging and amyloid promote microglial cell senescence. Rejuvenation Res 2007; 10: 61-74.
34. Grandbarbe L, Michelucci A, Heurtaux T, et al. Notch signaling modulates the activation of microglial cells. Glia 2007; 55: 1519-1530.
35. Rolls A, Shechter R, London A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med 2008; 5: e171.
36. Maillard I, Adler SH, Pear WS,. Notch and the immune system. Immunity 2003; 19: 781-791.
37. Minter LM, Turley DM, Das P, et al. Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol 2005; 6: 680-688.
38. Arumugam TV, Chan SL, Jo DG, et al. Gamma secretase-mediated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Nat Med 2006; 12: 621-623.
39. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216.
40. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-5714.
41. Behbahani H, Shabalina IG, Wiehager B, et al. Differential role of presenilin-1 and -2 on mitochondrial membrane potential and oxygen consumption in mouse embryonic fibroblasts. J Neurosci Res 2006; 84: 891-902.
42. Pigino G, Pelsman A, Mori H, Busciglio J,. Presenilin-1 mutations reduce cytoskeletal association, deregulate neurite growth, and potentiate neuronal dystrophy and tau phosphorylation. J Neurosci 2001; 21: 834-842.
43. Trinchese F, Liu S, Battaglia F, et al. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004; 55: 801-814.
44. Richards JG, Higgins GA, Ouagazzal AM, et al. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 2003; 23: 8989-9003.
45. Lee J, Chan SL, Mattson MP,. Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromolecular Med 2002; 2: 29-45.
46. von Bernhardi R, Ramirez G, Toro R, Eugenin J,. Pro-inflammatory conditions promote neuronal damage mediated by amyloid precursor protein and decrease its phagocytosis and degradation by microglial cells in culture. Neurobiol Dis 2007; 26: 153-164.
47. Takahashi K, Rochford CD, Neumann H,. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 2005; 201: 647-657.
48. Saura CA,. Presenilin/gamma-secretase and inflammation. Front Aging Neurosci 2010; 2: 16.